What amount sold does LigoCyte Pharmaceuticals Inc report in Form D filings?

The latest linked filings report $14.1M sold across 3 identified offering(s). 1 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was LigoCyte Pharmaceuticals Inc's most recent SEC filing?

LigoCyte Pharmaceuticals Inc's most recent Form D filing was on 2012-06-28.

How many investors does LigoCyte Pharmaceuticals Inc have?

The most recent Form D filing lists 7 investor(s).

What type of securities does LigoCyte Pharmaceuticals Inc offer?

LigoCyte Pharmaceuticals Inc's SEC Form D filings indicate equity, debt offerings.

LigoCyte Pharmaceuticals Inc

CIK: 0001400794·Pharmaceuticals·Bozeman, MT·Corporation·Founded 2008

Reported Sold

$14,072,305

Total Filings

Identified Offerings

Last Filed

Jun 28, 2012

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately. 1 unlinked amendment excluded.

About

Company in Pharmaceuticals industry

SEC EDGAR

Offering filing timeline

Jun 28, 2012Form D — New notice

Reported sold: $2,000,000 · Target: $22,094,465

Rule 506·7 investors

Jun 21, 2011Form D — New notice

Reported sold: $5,500,000 · Target: $13,080,283

Rule 506·11 investors

May 28, 2010Form D/A — Amendment

Reported sold: $6,572,305 · Target: $14,661,296

Rule 506·15 investors

Changed: Reported amount sold, Offering target, Reported investors

Apr 22, 2010Form D — New notice

Reported sold: $6,500,000 · Target: $14,500,000

Rule 506·11 investors

Aug 14, 2009Form D/A — Amendment

Reported sold: $29,490,335 · Target: $29,490,335

No verified predecessor available.

Rule 506·23 investors

Fundraising Profile

Exemptions

Rule 506

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

Amendment Rate

40%

Latest reported sold across 3 identified offerings

$14,072,305

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

1 unlinked amendment excluded.

Key People

ROBERT GOODWIN

Related Person

Appears on 3 filings

Donald Beeman

Related Person

Appears on 3 filings

Larry Mikkola

Related Person

Appears on 3 filings

Ivor Royston

Related Person

Appears on 3 filings

Ben Auspitz

Related Person

Appears on 3 filings

J. Donald deBethizy

Related Person

Appears on 3 filings

C. Boyd Clarke

Related Person

Appears on 3 filings

Markus Goebel

Related Person

Appears on 3 filings

Filing History

Date	Type	Offering target	Reported sold	Investors
Jun 28, 2012	New	$22,094,465	$2,000,000	7
Jun 21, 2011	New	$13,080,283	$5,500,000	11
May 28, 2010	Amendment	$14,661,296	$6,572,305	15
Apr 22, 2010	New	$14,500,000	$6,500,000	11
Aug 14, 2009	Amendment	$29,490,335	$29,490,335	23

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

Vesalius Longevity Labs Inc.

Pharmaceuticals

Offering target: $30,112,500

Filed Nov 3, 2026